Homepage
Healthcare · Biotechnology · United States · Updated May 11, 1:52pm
$0.10
Price
$275
Market Cap
26
Employees
0.75
Beta
Amro A. Albanna
CEO
Business Description
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Business History
Price Overview
Last updated: May 11, 2026 1:52pm (just now)$0.10
-0.02 (-14.06%)
Day Range
$0.10 – $0.11
52-Week Range
$0.10 – $1,979.76
50-Day MA
$1.18
200-Day MA
$274.88
Volume
1,544,751.00
Analyst Price Targets
Low
$1,280.00
Consensus
$1,280.00
High
$1,280.00
(1 analysts)
Share Structure
Outstanding
2,689.00
Float
2,689.00
Free Float
100.0%
High free float
— 100.0% of shares trade freely, ~0% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (0.0M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
0.00
Stock Price: $0.10
EPS (Diluted): -1,153.83
EPS (Diluted): -1,153.83
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.44
Stock Price: $0.10
Total Equity: $5.61M
Shares: 373,550
Total Equity: $5.61M
Shares: 373,550
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
4.79
Market Cap: $275.00
Total Debt: $3.01B
Cash: $3.20B
EBITDA: -$40.13M
Total Debt: $3.01B
Cash: $3.20B
EBITDA: -$40.13M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
-$189.6M
Market Cap: $275.00
Total Debt: $3.01B
Cash: $3.20B
Total Debt: $3.01B
Cash: $3.20B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
8.4%
Gross Profit: $268.00
Revenue: $3,195
Revenue: $3,195
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-612,542.2%
Operating Income: -$19.57M
Revenue: $3,195
Revenue: $3,195
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,305,608.8%
Net Income: -$41.71M
Revenue: $3,195
Revenue: $3,195
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-608.4%
Net Income: -$41.71M
Total Equity: $5.61M
Total Equity: $5.61M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-0.7%
Operating Income: -$19.57M
Tax Rate: 0.0%
Equity: $5.61M
Total Debt: $3.01B
Cash: $3.20B
Tax Rate: 0.0%
Equity: $5.61M
Total Debt: $3.01B
Cash: $3.20B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.31
Current Assets: $3.82M
Current Liabilities: $12.22M
Current Liabilities: $12.22M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
535.95
Short-Term Debt: $2.66B
Long-Term Debt: $342.90M
Total Debt: $3.01B
Total Equity: $5.61M
Long-Term Debt: $342.90M
Total Debt: $3.01B
Total Equity: $5.61M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.01
Revenue: $3,195
Shares: 373,550
Shares: 373,550
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$15.02
Total Equity: $5.61M
Shares: 373,550
Shares: 373,550
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-68,804.98
Operating CF: -$25.69B
CapEx: -$13.74M
Shares: 373,550
CapEx: -$13.74M
Shares: 373,550
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.10
Stock Price: $0.10
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$41.71M
Net Income: -$41.71M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ADTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $105,034 | $933,715 | $645,176 | $133,985 | $3,195 |
| Cost of Revenue | $77,979 | $766,779 | $756,836 | $627,474 | $2,927 |
| Gross Profit | $27,055 | $166,936 | $-111,660 | $-493,000 | $268 |
| Operating Expenses | $42.0M | $25.6M | $26.0M | $27.4M | $19.6M |
| Operating Income | -$41.9M | -$25.5M | -$26.1M | -$27.9M | -$19.6M |
| Net Income | -$46.4M | -$27.7M | -$32.4M | -$34.4M | -$41.7M |
| EBITDA | -$44.0M | -$24.8M | -$25.5M | -$27.0M | -$40.1M |
| EPS | $-2.43 | $-14.89 | $-249,623.74 | $-346,053.00 | $-1,153.83 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $7.9M | $2.8M | $97,102 | $833,031 | $3.2B |
| Total Current Assets | $9.4M | $4.7M | $6.9M | $2.0M | $3.8M |
| Total Assets | $16.7M | $10.7M | $44.6M | $32.1M | $16.5M |
| Current Liabilities | $3.6M | $3.6M | $25.9M | $23.4M | $12.2M |
| Long-Term Debt | $110,041 | $0 | $0 | $0 | $342.9M |
| Total Liabilities | $6.5M | $5.5M | $28.5M | $23.9M | $12.6M |
| Total Equity | $10.2M | $5.2M | $16.1M | $8.9M | $5.6M |
| Retained Earnings | -$67.4M | -$95.0M | -$127.7M | -$168.1M | -$209.8M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$22.3M | -$22.4M | -$18.6M | -$16.8M | -$25.7B |
| Capital Expenditure | -$1.0M | $-367,079 | $-14,407 | $0 | -$13.7M |
| Free Cash Flow | -$23.3M | -$22.8M | -$18.6M | -$16.8M | -$25.7B |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $-20,000 | $-1,000 | -$2.9M | -$9.2M |
| Net Change in Cash | -$2.6M | -$5.1M | -$2.7M | $735,929 | $2.4B |
Analyst Estimates (Annual)
| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$1.2M $1.2M – $1.2M
|
$1.3M $1.3M – $1.3M
|
$1.3M $1.3M – $1.3M
|
$1.4M $1.4M – $1.4M
|
| EBITDA |
-$1.2M -$1.2M – -$1.2M
|
-$1.3M -$1.3M – -$1.3M
|
-$1.3M -$1.3M – -$1.3M
|
-$1.4M -$1.4M – -$1.4M
|
| Net Income |
-$310.6T -$310.6T – -$310.6T
|
-$315.8T -$315.8T – -$315.8T
|
-$321.2T -$321.2T – -$321.2T
|
-$36.1M -$36.1M – -$36.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +789.0% | -30.9% | -79.2% | -97.6% |
| Gross Profit Growth | +517.0% | -166.9% | -341.5% | +100.1% |
| Operating Income Growth | +39.2% | -2.3% | -6.9% | +29.8% |
| Net Income Growth | +40.4% | -17.1% | -6.4% | -21.1% |
| EBITDA Growth | +43.5% | -2.5% | -6.2% | -48.4% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-23 | HRT FINANCIAL LP | S-Sale | 3,811.00 | $0.29 | $1,105 |
| 2026-04-24 | HRT FINANCIAL LP | S-Sale | 29,404.00 | $0.28 | $8,233 |
| 2026-04-21 | HRT FINANCIAL LP | P-Purchase | 72,912.00 | $0.33 | $24,061 |
| 2026-04-22 | HRT FINANCIAL LP | S-Sale | 11,982.00 | $0.30 | $3,595 |
| 2026-04-21 | HRT FINANCIAL LP | 0.00 | $0.00 | $0 | |
| 2025-12-17 | Brady Brian Michael | S-Sale | 1.00 | $1.75 | $2 |
| 2025-11-25 | Pankovcin Corinne | S-Sale | 1.00 | $3.20 | $3 |
| 2025-09-30 | Porcelli Christopher Jon | 0.00 | $0.00 | $0 | |
| 2024-10-23 | Hermina Sylvia | 0.00 | $0.00 | $0 | |
| 2025-06-05 | PELLETIER SAUNDRA L | 0.00 | $0.00 | $0 | |
| 2024-10-15 | HRT FINANCIAL LP | P-Purchase | 15,636.00 | $1.50 | $23,454 |
| 2024-10-16 | HRT FINANCIAL LP | S-Sale | 25,534.00 | $1.17 | $29,875 |
| 2024-10-15 | HRT FINANCIAL LP | 0.00 | $0.00 | $0 | |
| 2023-11-08 | Runge Jeffrey W. | A-Award | 470.00 | $5.01 | $2,355 |
| 2023-11-08 | Albanna Rowena | A-Award | 4,702.00 | $5.01 | $23,557 |
| 2023-11-08 | Nelson Charles Athle | A-Award | 470.00 | $5.01 | $2,355 |
| 2023-11-08 | Albanna Amro A. | A-Award | 9,404.00 | $5.01 | $47,114 |
| 2023-11-08 | Pankovcin Corinne | A-Award | 4,702.00 | $5.01 | $23,557 |
| 2023-11-08 | Farley Thomas J | A-Award | 4,702.00 | $5.01 | $23,557 |
| 2023-11-08 | Brady Brian Michael | A-Award | 470.00 | $5.01 | $2,355 |
No community reviews yet for ADTX.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27